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Abstract Inflammatory joint diseases are a group of
heterogeneous disorders with a variety of different etiolo-
gies and disease manifestations. However, there are features
that are common to all of them: first, the recruitment of
various inflammatory cell types that are attracted to
involved tissues over the course of the disease process.
Second, the treatments used in many of these diseases are
commonly medications that suppress or alter immune
function. The demonstration that adenosine has endogenous
anti-inflammatory functions and that some of the most
commonly used anti-rheumatic medications exert their
therapeutic effects through stimulation of adenosine release
suggest an important role for purinergic signaling in
inflammatory rheumatic disorders.
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Inflammatory joint diseases are a heterogenous group of
disorders afflicting not only joint tissues but often multiple
organs in the body. While known etiologies differ among
the variety of diseases, treatment often involves medica-
tions with immuno-modulatory functions. It has been
known for a long time that deficiency of adenosine
deaminase, the principal catabolizing enzyme for adenosine
and deoxyadenosine, is associated with immunity dysfunc-
tion. Indeed, one-third of patients with autosomal recessive
severe combined immunodeficiency exhibit adenosine
deaminase deficiency. The disorder is characterized by
abnormal development of lymphocytes in the thymus and
may affect maturation of T cells as well as that of B cells
[1]. This suggests that endogenous adenosine might have an
important immunosuppressive role. The immune effects of
adenosine deaminase deficiency have been well studied in
animal models of this disease. It appears that the toxic
effects on T and B lymphocytes are related to increased
concentrations of 2′-deoxyadenosine, which, through vari-
ous mechanisms, increase the rate of apoptosis in the
developing thymocytes [2, 3]. With the discovery of the
effects of adenosine in modulating the generation of free
oxygen radicals in neutrophils, it was clear that the effects
of adenosine on the immune system were widespread and
not limited to lymphocytes alone [4]. As interest in the anti-
inflammatory effects of adenosine grew, it became known
that the release of adenosine is important in mediating the
therapeutic effects of methotrexate, one of the most widely
used disease-modifying medications for rheumatoid arthri-
tis. We will explore some of the physiological mechanisms
of adenosine and its receptors relevant to the perpetuation
as well as treatment of the rheumatic diseases (Fig. 1).
The cellular components of inflammatory joint diseases
Neutrophils
A hallmark of the inflammatory response is the recruitment
of inflammatory cells into the site of inflammation.
Histological observation of the cell types involved has
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Early observers have identified the polymorphonuclear
neutrophil as an important player in the acute inflammatory
response. These cells, when activated, can generate inflam-
matory damage via various mechanisms. One of the most
important of these mechanisms is the generation of free
oxygen radicals. In the initiation phase of oxygen radical
formation, an NADPH oxidase is assembled within the
membrane and the superoxide anion is generated from
molecular oxygen in a chain of chemical reactions. There
are many known physiological stimulators for the superox-
ide anion, including the chemo-attractant N-formyl-
methionyl-leucyl-phenylalanine (FMLP), the complement
component C5a, and artificial stimulants such as the calcium
ionophore A23187. In 1983 it was shown for the first time
that adenosine can dramatically suppress the generation of
superoxide anions in neutrophils via interaction with cell
surface receptors, which was thought to be the A2 receptor at
the time [4–7]. The inhibition of superoxide anion
generation was reversed by the addition of adenosine
deaminase to the FMLP-stimulated neutrophils in culture.
Furthermore, Gαs receptor stimulation led to a rise in
intracellular 3′,5 ′ cyclic adenosine monophosphate
(cAMP), and inhibition of protein kinase A downstream
of this signaling pathway by the inhibitor KT5720 reversed
the effects of cAMP analogs but not adenosine receptor
agonists on superoxide anion generation in the stimulated
neutrophils. These observations are somewhat controver-
sial, as Sullivan et al. have reported that cAMP and protein
kinase A mediate the effects of adenosine receptor
occupancy in tumor necrosis factor (TNF)-treated neutro-
phils [8]. Recent observations suggest that it is possible that
cAMP–protein kinase A-mediated effects are more impor-
tant in regulating function in TNF-treated cells because of
the dramatic increase in cAMP generated in TNF-treated
cells [9–11]. It was later reported that the receptor in
question responsible for these functions was, indeed, the
adenosine A2A receptor [12, 13]. These findings led to
interest in the immuno-modulatory functions of adenosine.
Not only is adenosine important in modulating neutro-
philic function, but, much earlier than that in the cascade of
inflammatory events, it also influences the recruitment of
cells into the inflammatory site by regulating the expression
of adhesion molecules [14–16]. Adhesion of the stimulated
neutrophil to the endothelium and its chemotaxis are
promoted by stimulation of the adenosine A1 receptor,
whereas stimulation of the A2 receptor suppresses neutro-
phil adhesion and the generation of oxygen radicals [17].
The effects on neutrophil adhesion are relevant to clinical
practice, since the expression of adhesion molecules has
been shown to be upregulated in circulating blood
neutrophils in real-life patients with diseases associated
with widespread inflammatory activation such as sepsis
[18]. Furthermore, adenosine A2A receptor activation
counteracts the enhancement of adhesion molecule expres-
sion in the stimulated neutrophils from these patients.
Those findings highlight the opposing roles of the A1 and
A2 receptors in inflammatory modulation, i.e., proinflam-
matory and anti-inflammatory, respectively. Transmigration
of the neutrophil through the endothelium, as well as the
release of vascular endothelial growth factor by neutrophils,
are both modulated by the A2B receptor [19].
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Fig. 1 The effects of adenosine
in inflammatory tissue
injury
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Cells of the monocyte–macrophage lineage are significant
contributors to tissue damage in the rheumatoid synovium.
Their capacity to do so is exemplified by their ability to
phagocytose opsonized particles, generate oxidant-induced
damage, and produce a whole host of proinflammatory
cytokines that augment the inflammatory response. These
cytokines can modulate the function and expression of
adenosine A2A as well as A2B receptors [9–11, 20].
Adenosine and its analogs can, in turn, regulate production
of these cytokines, as well as nitric oxide synthase
expression in macrophages [20, 21].
Lipopolysaccharide-induced interleukin (IL)-12 produc-
tion by monocytes and macrophages is an effect mediated by
toll-like receptor-4 (TLR4), and IL-12 elicits a strong
inflammatory response. Adenosine exerts its anti-inflamma-
tory effects in part by suppressingthe production of IL-12 [9,
22–24]. Much like the case with neutrophils, FMLP
induces the generation of superoxide anions in monocytes.
Adenosine, in micromolar concentrations, suppresses this
respiratory burst response to FMLP but not to the
induction of phorbol myristate acetate [25]. The
Fc gamma receptor serves an important function in
mediating phagocytosis in monocytes. Stimulation of the
adenosine A1 receptor promotes Fc gamma receptor-
mediated phagocytosis by monocytes, whereas A2 receptor
agonists suppress phagocytosis. Another example of the
opposing effects of A1 and A2 receptors can be seen with
multi-nucleated giant cell formation. Multi-nucleated giant
cells, formed by the fusion of multiple macrophages, are a
distinctive feature of the subcutaneous nodules. These are
seen both as a manifestation of rheumatoid arthritis itself
and as a consequence of one of its most common drug
treatments, methotrexate. Multi-nucleated giant cell forma-
tion from stimulated human monocytes is promoted by A1
receptor stimulation, while activation of the A2 receptor has
the opposing effect [26].
Dendritic cells are also important players in antigen
presentation, and they too express adenosine receptors.
Lipopolysaccharide induces maturation of dendritic cells,
and, as they mature, the A1 and A3 receptor message is
downregulated, while no change is observed with A2A
receptor mRNA [27]. Following activation of the dendritic
cell, A2A receptor ligation inhibits its production of IL-12,
much as occurs in macrophages [24]. Other cytokine-
modulating effects exist, to include suppression of tumor
necrosis factor-α as well as enhancement of secretion of the
anti-inflammatory cytokine, interleukin-10 [28]. These
effects are also attributable to the A2A receptor. Further-
more, dendritic cells that matured in the presence of
adenosine were less able to promote the differentiation of
CD4-positive naïve T lymphocytes towards a Th1-pheno-
type, and this has great implications in limiting a T cell-
initiated proinflammatory response [28].
Lymphocytes
The T lymphocyte remains one of the key cell types
responsible for the inflammatory state in the rheumatoid
synovium. At low concentrations of extracellular adeno-
sine, inhibition of T cell receptor-triggered proliferation and
induction of interleukin-2α chain expression has been
observed, and these may be important contributing mech-
anisms for causing peripheral T cell depletion [29]. These
effects are mediated through the adenosine A2A receptor.
Indeed, adenosine acts as a strong suppressant of many
known T cell receptor-triggered effector functions of
T lymphocytes, such as induced FasL expression on
cytotoxic T lymphocytes. While exposure to ligands may
be brief, effector functions and cellular changes in cAMP
may be more prolonged and contribute to T cell memory
[30]. Much as the response to ligand activation varies
among T lymphocytes, adenosine receptor expression is
also cell type-dependent, and lymphokine-producing
T helper cells have been cited to be much more likely to
express A2A receptors [31]. T cell receptor activation is
associated with a rapid induction of adenosine A2A receptor
message expression, and A2A receptor activation profound-
ly suppresses T cell receptor-mediated interferon-γ produc-
tion [32]. Thus, adenosine A2A receptor activation is
generally beneficial for the impairment of T lymphocyte-
triggered events in the pathogenesis of rheumatic disease.
Endothelial cells
The vascular endothelium limits the flow of traffic between
the vascular lumen and surrounding tissues, and as such, it
serves an important function in regulating the influx of
inflammatory cells into the site of inflammation. Activation
of the endothelium may result from the influence of a vast
number of inflammatory mediators, including cytokines
such as tumor necrosis factor-α and interleukin-1 as well as
immune components such as immune complexes and
complement components. Endothelial permeability is in-
creased by oxidant injury, and the resultant extravasation of
fluid normally contained within the vessel lumen can be
seen as inflammatory edema. The neutrophil, once activat-
ed, is induced to release AMP and adenosine, which
augments this barrier function in an in vitro endothelial
paracellular permeability model [33]. The endothelium has
the intrinsic ability to generate adenosine by dephosphor-
ylation of AMP through the action of 5′-ectonucleotidase.
Passage of Evan’s blue dye-labeled albumin across conflu-
ent monolayers of human umbilical vein endothelial cells
(HUVECs) is hampered in the presence of adenosine, a
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[34]. Others have argued that the function of the endothelial
barrier is more closely related to adenosine A2B receptor
activation, since A2B receptor antagonists effectively
reverse ATP-induced changes in endothelial permeability
following hypoxic insult [35]. These data demonstrate that
adenosine exerts its overall anti-inflammatory function in
part by limiting extravasation at the endothelial level. In
contrast, adenosine has also been reported to induce
apoptosis in endothelial cells, a physiological activity that
requires protein tyrosine phosphatase [36]. The outflow of
inflammatory cells is similarly suppressed in the presence
of adenosine. This occurs as a result of alteration in
adhesion molecule expression such as E-selectin and
vascular cell adhesion molecule-1 (VCAM-1) in the
presence of adenosine [37]. In addition, dose-dependent
suppression of the expression of inflammatory cytokines
IL-6 and IL-8 by stimulated HUVECs has also been
observed [37]. Proliferation of endothelial cells is stimulat-
ed by the presence of adenosine, and this signals a role for
adenosine in the promotion of angiogenesis, since neo-
vascularization in the retina is suppressed by ribozymes that
cleave A2B receptor mRNA [38, 39]. The proliferative
effect is, in part, mediated through induction of the
formation of vascular endothelial growth factor [40].
Response to adenosine receptor occupancy varies between
cell types, since agonist-induced upregulation of interleu-
kin-8, vascular endothelial growth factor and basic fibro-
blast growth factor occurs in human microvascular
endothelial cells (HMEC-1) but not HUVECs [41]. This
effect, attributable to A2B receptor activation, occurs via Gq
and possibly G12/13 coupling. Tissue hypoxia has a
modulatory effect on endothelial adenosine receptor ex-
pression in favor of an A2B pro-angiogenic phenotype [42].
The adenosine A2A receptor also has an important role to
play in regulating angiogenesis. A2A receptor stimulation in
primary human endothelial cells is known to activate the
mitogen-activated protein kinase signaling pathway [43].
Using a murine air pouch model, Montesinos et al. first
demonstrated that angiogenesis is inhibited in adenosine
A2A receptor-deficient mice compared with wild-type
littermates [44, 45]. It is now known that this occurs at
least in part by a reduction in the expression of the anti-
angiogenic matrix protein thrombospondin-1 and increased
macrophage production of vascular endothelial growth
factor [46, 47]. Moreover, topical adenosine A2A receptor
agonists stimulate recruitment of endothelial precursor cells
from the bone marrow to injured sites [45].
Mast cells
Adenosine is known to be a stimulus for mast cell
degranulation. It has been demonstrated that this may occur
through A3 receptor ligation, though it is interesting to note
that inosine can also bind to the A3 receptor and cause
degranulation of the mast cell [48, 49]. Since mast cell
degranulation is generally thought of as a potent proin-
flammatory signal, it is difficult to reconcile this seemingly
untoward physiological function with the overall anti-
inflammatory nature of adenosine release. One possible
explanation is that the release of histamines contained
within the granules is a stimulus for suppression of the
production of tumor necrosis factor-α and interleukin-12
while enhancing the release of the anti-inflammatory
interleukin-10, at least in a murine model of endotoxemia
[50]. Furthermore, upregulation of Th2 cytokines in mast
cells may affect the immune function of other cell types,
since adenosine-activated mast cells induce the production
of IgE by B lymphocytes, an effect mediated by the
adenosine A2B receptor [51].
Methotrexate
Treatment of rheumatoid arthritis took a great leap half a
century ago with the discovery of the beneficial effects of
corticosteroids on this disease, a discovery that was, indeed,
crowned by the award of a Nobel prize. It was around this
time that methotrexate came into clinical use. While long in
use for the treatment of malignant diseases, the use of
methotrexate in rheumatoid arthritis has only become
widespread in the past 20 years [52–54]. Since then, it
has been a mainstay of rheumatoid therapy, and its
popularity, as well as its efficacy, in this disease has
remained undisputed, even with the appearance of newer
biological agents.
Methotrexate was originally developed as an anti-folate
agent. As such, it has antiproliferative properties against
immune cells active in the flaring rheumatoid synovium,
such as the lymphocyte. This was indeed thought to be
the principal mechanism of action of methotrexate in
rheumatoid arthritis. Methotrexate induces clonal deletion
of activated T lymphocytes in mixed lymphocyte reac-
tions, and this effect holds true for peripheral blood
lymphocytes taken from patients with rheumatoid arthritis
[55]. However, the effect is short-lived, making it difficult
to explain why administration of methotrexate in a dose
frequency of only once a week, as is normally the case in
rheumatoid arthritis treatment, could result in clinical
immunosuppression from its lymphocyte antiproliferative
properties alone.
Other theories have existed to explain the anti-inflam-
matory actions of methotrexate. Since methotrexate is an
inhibitor of dihydrofolate reductase, it suppresses tetrahy-
drofolate synthesis. Tetrahydrofolate is a methyl group
donor that enables the formation of methionine from
homocysteine. A metabolite of methionine, S-adenosyl-
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polyamines spermine and spermidine. These polyamines
are processed by immune cells, including monocytes,
resulting in toxic metabolites. Thus, methotrexate can
inhibit the formation of detrimental polyamines. It has been
shown that methotrexate can inhibit the generation of
spermine and spermidine in stimulated rheumatoid lym-
phocytes [56]. Inhibitors of polyamine production in-
creased interleukin-2 production by peripheral blood
mononuclear cells from rheumatoid arthritis patients,
suggesting that polyamines may be associated with
diminution of T cell effector function [57]. Urinary
polyamine levels are increased in patients with rheumatoid
arthritis and may be associated with disease activity [58].
These effects are, however, reversed by folic acid, and are
therefore insufficient to explain the anti-inflammatory
effects of low-dose methotrexate that are unaffected by
folic acid administration.
In the molecular pathways leading to the de novo
synthesis of purines, accumulation of various intermediates
can lead to the release of adenosine [59]. Methotrexate can
be thought of as a prodrug. Once ingested, it is taken up by
cells via the reduced folate carrier and, in turn, polygluta-
mated [60]. These polyglutamates, which remain in cells
for time periods measured in weeks, are potent inhibitors of
one of the key enzymes involved in the de novo
biosynthesis of purines, aminoimidazole-carboxy-amido-
adenosine ribonucleotide (AICAR) transformylase [61–
63]. This enzyme inhibition effect occurs at pharmacolog-
ically relevant concentrations of methotrexate and can
readily explain the clinically persistent anti-inflammatory
effect of the infrequent once-a-week dosing interval. Thus,
it is likely that the principal mechanism of action of low-
dose methotrexate as used in inflammatory joint diseases
such as rheumatoid arthritis is different from its cellular
effects as a chemotherapeutic agent. Urinary excretion of
aminoimidazole carboxamide was increased following
methotrexate administration in a rat adjuvant arthritis model
[64]. Inhibition of AICAR transformylase leads to an
increase in its substrate, AICAR. The accumulation of
AICAR, in turn, has important effects on key enzymes that
influence adenine nucleotide metabolism. AICAR itself is
an inhibitor of AMP deaminase, which converts AMP to
inosine monophosphate. A metabolite of AICAR, amino-
imidazole-carboxamido-ribonucleoside (AICAside), inhib-
its adenosine deaminase. The net effect of AICAR
accumulation, therefore, is a rise in intracellular AMP and
adenosine levels, an effect known to occur with methotrex-
ate in pharmacological concentrations in animal models
[14, 65].
These AMP and adenosine elevating effects of metho-
trexate are supported by various lines of evidence in vivo.
The development of adjuvant arthritis in the rat was
suppressed by direct infusion of adenosine into the knee
[66]. 8-Phenyl theophylline, a non-selective adenosine
receptor antagonist, exacerbated leukotriene B4-mediated
inflammatory responses in a hamster cheek pouch model of
inflammation, suggesting that adenosine itself plays an anti-
inflammatory role [67]. Szabo et al. reported that an
adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adeno-
sine-5′-N-methyl-uronamide (IB-MECA), reduced the se-
verity of joint inflammation in a collagen-induced model of
arthritis. This was accompanied by a reduction in neutrophil
infiltration and suppression of macrophage inflammatory
protein (MIP)-1α production in the paws of the animals
[68].
We first reported that weekly treatment with methotrex-
ate increased splenocyte AICAR concentrations and also
increased adenosine levels in inflammatory exudates [14].
Blockade of adenosine receptors reversed the anti-inflam-
matory effects of methotrexate. Similarly, Montesinos et al.
showed that weekly doses of methotrexate increased
adenosine levels in the exudates of inflamed murine air
pouches, which was associated with a decrease in leukocyte
accumulation and tumor necrosis factor-α production,
effects not seen in adenosine A2A or A3 receptor-deficient
mice [69]. The non-selective adenosine receptor antago-
nists, theophylline and caffeine, both reversed the beneficial
effects of methotrexate in a rat adjuvant arthritis model of
rheumatoid arthritis, as evidenced by disease severity index,
hindpaw swelling, and hindpaw ankylosis [70].
Interestingly, the observation that caffeine reverses the
anti-inflammatory effects of methotrexate has also been
noted in humans. Silke et al. first reported that coffee
ingestion was associated with poor clinical response to
methotrexate, and patients with high caffeine intake were
more likely to discontinue methotrexate treatment, presum-
ably because of lack of response [71]. Coffee itself has been
reported to have been directly correlated with rheumatoid
factor positivity, and consumption of more than four cups
of coffee a day was associated with a greater risk of
developing frank rheumatoid factor-positive rheumatoid
arthritis [72]. Nesher et al. have confirmed the reduction
in efficacy of methotrexate treatment by caffeine consump-
tion in patients with rheumatoid arthritis [73]. Recently,
Ralph and colleagues reported that reduction in synovial
expression of the orphan nuclear receptor NURR1 is the
first change observed in patients treated with methotrexate
and that the effects of methotrexate on NURR1 are
mediated by adenosine acting at A2A receptors [74].
Although we have focused our discussion on methotrex-
ate, other anti-rheumatic and immuno-modulatory agents
have also been shown to exert their anti-inflammatory
effects in an adenosine-dependent manner. Most important
among these are sulfasalazine [75, 76], FK506 [77] and
aspirin [78, 79].
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The role of adenosine in the modulation of inflammation
has been appreciated only in recent years, yet this
Cinderella of the inflammatory response has a clear
influence on many cell types that govern the pathogenesis
of inflammatory rheumatic diseases. The role of cytokines
in the mediation of rheumatic joint damage has been
exploited in recent anti-rheumatic drug development.
Adenosine also has a part to play in modulating the
generation of cytokines relevant to the development of
rheumatic diseases. The overall effects of adenosine, often
beneficial in rheumatic disease, are exemplified by its
involvement in commonly used anti-rheumatic drug treat-
ments. Adenosine analogs may one day find their way into
the clinic.
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